Capitala Group and Pike Street Capital Invest $19.5M in US BioTek Laboratories

January 8, 2019

Capitala Group, alongside Pike Street Capital, provided a $19.5 million financing package (senior secured debt and equity) to US BioTek Laboratories to support the company's next phase of growth. The capital will fund expansion of US BioTek's specialty immunology and allergy testing capabilities as well as sales and marketing initiatives.

Buyers
Capitala Group, Pike Street Capital
Targets
US BioTek Laboratories LLC
Location
Washington, United States
Transaction Type
Growth capital

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.